Physician profile
Daniel Daroszewski
NPI 1073049987
$4,213.58
in general payments reported to CMS, 2019-2025
20 companies · $782 in 2025
The $782 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $558 · 2020: $18.48 · 2021: $475 · 2022: $272 · 2023: $814 · 2024: $1,294 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,854 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17.86 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,853.81 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17.86 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,481.50 | 2019-2025 | Lensx, Clareon, Clareon Panoptix Pro |
| Harrow Eye, LLC | $356.28 | 2023-2025 | Iheezo, Vevye |
| Sight Sciences, INC. | $258.30 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Oyster Point Pharma, INC. | $233.09 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Rxsight INC | $222.59 | 2022-2024 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Johnson & Johnson Surgical Vision, INC. | $214.33 | 2023-2025 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Glaukos Corporation | $170.57 | 2021-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Abbvie INC. | $164.26 | 2023-2025 | Durysta |
| Horizon Therapeutics Plc | $146.31 | 2021-2023 | Tepezza |
| Carl Zeiss Meditec USA, INC. | $132.57 | 2024 | |
| Biotissue Holdings INC. | $125.13 | 2024-2025 | |
| Amgen INC. | $124.99 | 2024 | Tepezza |
| Ivantis, INC | $121.26 | 2021 | |
| Sun Pharmaceutical Industries INC. | $117.20 | 2024 | |
| Dompe US, INC. | $105.47 | 2022-2025 | Oxervate |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $95.17 | 2023-2024 | Miebo, Xiidra, Revive |
| Mallinckrodt Hospital Products INC. | $82.95 | 2024 | Acthar |
| Novartis Pharmaceuticals Corporation | $23.07 | 2023 | |
| Astellas Pharma US INC | $21.41 | 2023 | |
| Eyepoint US, INC. | $17.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Daroszewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.